Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma.
Effects of fumaric acid esters on blood-brain barrier tight junction proteins.
UCSF Seminar: "How do we get a myelinated brain? A new model for distribution of oligodendrocytes throughout the developing CNS"
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Episode 3 with Drs. Daren Austin and Susan Van Meter on the MIRROR trial of ofatumumab
Evidence for Mitoxantrone-induced Block of Inwardly Rectifying K Channels Expressed in the Osteoclast Precursor RAW 264.7 Cells Differentiated with Lipopolysaccharide.
The cell biology of CNS myelination.
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis.
Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin.
Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?
American Neurological Association Annual 2012 Annual Meeting
Neurological involvement in Primary Sjögren Syndrome.
Daclizumab in multiple sclerosis: a high-yield extension study.
PML in a patient treated with fumaric acid.
Assessment of cancer risk with β-interferon treatment for multiple sclerosis.
Central fatigue in multiple sclerosis: a review of the literature.
Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study.
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
Product Portfolio, Meda
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio
Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
A Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)

Pages